RELMADA THERAPEUTICS, INC. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Relmada Therapeutics, Inc. (RLMD) on September 8, 2026, covering the event date of September 3, 2026. The company is incorporated in Nevada and trades on the NASDAQ Capital Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate governance event rather than financial performance.
Material Changes
Under Item 8.01 (Other Events), the company reported the termination of employment for Dr. Raj S. Pruthi, who served as Chief Medical Officer – Urology. His employment ended on September 3, 2026.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies related to the departure of Dr. Pruthi. No unusual items were disclosed.
Investor Verification Checklist
- Verify the official reason for Dr. Pruthi's departure and whether it was voluntary or involuntary.
- Confirm if a replacement for the Chief Medical Officer – Urology role has been identified or is in the recruitment process.
- Assess the potential impact of this leadership change on ongoing urology clinical trials or product development pipelines.
- Review subsequent press releases or 10-Q/10-K filings for any financial implications of this personnel change.